Prime Medicine, Inc. (PRME) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $5.81M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $63.97M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value (m); Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $5.81M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $5.81M |
| Deferred revenue · latest quarter (USD) | $63.97M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $7.93M + $56.03M ≈ $63.97M |
| Other obligations · due within 1 year (USD) | (m) | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Other obligations · due after 1 year (USD) | (m) | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Total reported obligations | 209.23M USD | Liabilities |
| Borrowing debt | (m) | |
| Amounts owed to suppliers | 5.81M USD | Accounts Payable, Current |
| Total deferred revenue | 63.97M USD | Contract with Customer, Liability, Current · Contract with Customer, Liability, Noncurrent |
| Deferred revenue due within one year | 7.93M USD | Contract with Customer, Liability, Current |
| Deferred revenue due after one year | 56.03M USD | Contract with Customer, Liability, Noncurrent · Contract with Customer, Liability, Current |
| Reported other obligations due within one year | (m) | |
| Reported other noncurrent obligations | (m) | |
| Deferred revenue included in other noncurrent obligations | 0.00 USD | Contract with Customer, Liability, Current |
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- (m)
- Other obligations · due after 1 year (USD)
- (m)
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $112.48M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $5.81M | $63.97M | (m) | (m) | $209.23M | (m) | $7.93M | $56.03M | (m) | $0.00 |
| 2026-03-31 | (m) | $12.32M | $65.09M | (m) | (m) | $218.03M | (m) | $7.32M | $57.77M | (m) | $0.00 |
| 2025-12-31 | (m) | $8.89M | $65.95M | (m) | (m) | $221.87M | (m) | $7.82M | $58.13M | (m) | $0.00 |
| 2025-09-30 | (m) | $9.35M | $66.70M | (m) | (m) | $223.19M | (m) | $6.95M | $59.75M | (m) | $0.00 |
| 2025-06-30 | (m) | $6.38M | $67.88M | (m) | (m) | $218.15M | (m) | $8.31M | $59.56M | (m) | $0.00 |
| 2025-03-31 | (m) | $10.03M | $68.87M | (m) | (m) | $221.24M | (m) | $8.21M | $60.66M | (m) | $0.00 |
| 2024-12-31 | (m) | $11.35M | $70.31M | (m) | (m) | $144.36M | (m) | $7.09M | $63.22M | (m) | $0.00 |
| 2024-09-30 | (m) | $5.43M | $71.92M | (m) | (m) | $143.28M | (m) | $9.28M | $62.64M | (m) | $0.00 |
| 2024-06-30 | (m) | $4.64M | (m) | (m) | (m) | $63.12M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $10.08M | (m) | (m) | (m) | $67.62M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $19.54M | (m) | (m) | (m) | $60.78M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $14.12M | (m) | (m) | (m) | $45.19M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $5.49M | (m) | (m) | (m) | $40.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $4.56M | (m) | (m) | (m) | $38.15M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $4.33M | (m) | (m) | (m) | $44.04M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $4.11M | (m) | (m) | (m) | $42.56M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.44M | (m) | (m) | (m) | $62.30M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |